Prior to Prometheus, Mr. Stenhouse spent over 25 years at AbbVie, most recently serving as Vice President of U.S. Immunology. In this capacity, Mr. Stenhouse oversaw U.S. sales and marketing teams for ...
As most advisors are well aware, high stock prices have pushed down the market’s dividend yield. Barron’s ran a screen for ...
November 12, 2024. More for You ...
AbbVie reports disappointing mid-stage data for its schizophrenia drug. Jason Snipe of Odyssey Capital still likes AbbVie ...
AbbVie (NYSE:ABBV) and its shareholders were dealt a major setback Monday morning after results from a late-stage trial on ...
More recent acquisitions in 2024—oncology firms Mirati and RayzeBio and neurology firm Karuna—also help support Bristol's strong overall pipeline and wide moat. Bristol has created a strong pipeline ...
US central bank lowered rates by another 25 basis points on Thursday. AbbVie, Chevron, and Elf Beauty could benefit from ...
Chicago, IL – November 8, 2024 – Today, Zacks Investment Ideas feature highlights AbbVie ABBV, Visa V and Comfort Systems USA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback